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~ Coronary Slanting During Acute Myocardial 
Infarction. Results From the Stent Without 
Coumadln French Registry 
Thierry Lef~we, Made-claude Modce, Ga~tan Karditon, Pierre Aubry, 
Gilles Zemour, Bernard Valeix. ICVPat~s Sud, France 
lntra coronary Thmmbus and acute M.! were till recently a confmind'¢ation to
coronary stenting, Ticlopidine has dramaticaly decreased the dsk of subacute 
thrombosis after stenting to the point that some patients were stentud dudng 
acute M.I in the registry. To evaluate the outcome of those Pts a retrospective 
analysis was conducted. 
All Pts (2901) included in the registry from March 1991-1995 had 11clo- 
ptdtno (250-500 rag/day) the day of PTCA for 1 month, aspirin (100-250 
mg/dey) for > 6 months and low molecular weight hepadn (antiXa 0.5-1) for 
I month in phase II (237 Pts), 15 days in phase III (521 Pts), 7 days in phase 
IV (960 Pts) and not in phase V (1183 Pts). 
Only 85 Pts (2.9%) had primary' or rescue PTCA with stenting dudng acute 
M,I (age 59.8 =E 11.3 years, 11% female). Indication for stenting was respec- 
tively: subop'-;mal result (26%), non occlusive dissection (28%), occlusive 
dissection (11%) and de novo lesion (35%). Stented coronary ~rtedes were 
LAD: 33%, RCA: 49%, Cx: 9%, L,M: 2% and Bypass: 5%, Palmaz-Schatz 
stsnfs were used in 74% of cases, AVE stents in 24% and other stents in 
2%. One stent was used in 80% of cases and > 1 in 20%). Balloon used for 
stentlng was 3.38 ± 0.46 mm in diameter with an inflation pressure of 123 :l: 
3.0 arm. No vascular complication, stroke or emergency CA6G occured at 1 
month follow-up. Subacute desure occurecl in 1.~,~ of cases, elective CABG 
in 1.2%, acute M,I in 2.4% and death in 5.9%. The composite nd-point of 
subacute closure, acute M.I., CABG and death occlJred in 8,2%. 
In conclusion: coronary stenting is leasable in acute M.I with a low rate 
of subacute closure. Randomised study are necessary to evaluate mid-term 
outcome compared to POBA. 
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~ Intrscorenary Stenttng In the Setting of Myocardial 
Infarction 
Michel R. Le May, Madno Labinez, Rob S,B. Beanlands, Louise A. LaramC~e, 
Ed O'Bden, Jear~Frencois Marquis, William L. Williams, Khalid AI-Sadoon, 
Richard F. Davies, Sharon Ann Keams, Helen L. Johansen, Lyall 
A. Higginson. Ottawa Heart Institute, Ottawa, Ontado, Canada 
Data on feasibility, safety and clinical OUtcome of intmcaronary stenting (ICS) 
in the setting of MI are limited. Palmaz-$chatz stents were inserted in 49 
patients admitted with acute MI between 01/94 and 05/95. Group A, (n = 23) 
were stented early, day 0 to 7 of MI and Group B, (n = 26~ were stentsd late, 
8-25 days post MI. Demographics in the two groups were similar except hat 
all patients with cardiogenic shock (n = 4) were in Group A (P < 0.05), Only the 
infarct-related artery was stented. Quantitative measurements were obtained 
on the target lesion before and after ICS Between Group A and Group B them 
was no difference in minimal luminal diameter (MLD) or % diameter stenosis 
(DS) before or after ICS. In Group A, MLD increased from 0.43 -~ 0.36 to 
2 58 :E 0.47 mm (P < 0,0001); in Group B, MLD increased from 0.55 :i: 0.33 
t ~} 2,61 :E 0.40 mm (P < 0.0001), Percentage DS decreased in Group A from 
83 ± 14 to 15 piusmn; 13 (P < 0.0001) and in Group B front 79:1:12 to 12 
:E 12 (P < 0.000t). Visible thrembus was present in 39% of Group A and in 
23% of Group B before ICS (P = 0.35) but was not associated with adverse 
outcome. Only one patient had visible thrembus post ICS which resolved 
with intracoronary urokinase. During hosptiatization, o patient experienced 
recurrent MI or required CABG; in Group A, 2 patients required repeat PTCA 
and one patient died. There were no events in Group B. At follow-up of 5.9 
4.0 months, ~ti Group A patients were free of recurrent MI, repeat PTCA, 
CABG, and death; 80% were free of angina. In Group B patients followed to 
7.3 :t: 4.5 months, there ware 2 deaths; 3 patients required repeat PTCA and 
no patient required CABG; 71% of the remaining patients were free of angina. 
Conclusion: IGS in the setting of MI is associated with excellent imme- 
diate angiogrsphic sucoe~ and favoumble clinical outcome, Intmcoronary 
thrombus does not preclude stenting in patients with ML 
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~ Ele~lve Stent Implantation In Acute Coronary 
Syndromes Induced by Thrombus Containing 
Lesions 
Migual Romere, Alfonso Medina, Jos~ Su~zrez de Lezo, Manuel Pan, 
Endque Hem~mdez, Jss~ Segura, Francisco MellOn, DJordje Pavlovic, Jes~ 
R. Ortega. Reina Sofia Hospital, Universfty of C~rdoba and Pine Hospital, 
University of Las Patinas, Spain 
The presence el angi0graphio thrombus in coronary lesions has been Identi- 
fled as a dsk factor for adverse events during percutaneous revascuiarization; 
the use of stents could theoretically be contraindicated because of the intrin. 
sic thmmbegenicity of the stent-wims. We postulated that the achievement 
of the highest lumen diameter in this setting, could overcome such an ad- 
verse thrembegenio combination. From a total of 812 patients (pts) treated 
hy stent implantation, we selected for study 87 having coronary lesions with 
angiographtc evidence, of intraiominal filling defects, and rest angina within 
the last 48 hours. At cardiac catheterization the responsible artery was totally 
occluded in 41 pts and severely stenoseo in 46 (mean 82 :E 12%). Be o 
fore treatment or a.qer ecanalizetion, intraluminal thrembus was always evi- 
denced. A etent was ~¢Janted trying to achieve an optimal umen size. After 
deployment the residual stenoals was 4 :l: 9%. The filling defect decreased, 
but persisted in 10 and disappeared in 77, All pts became asymptomatic; 
38 of them received conventional antithrembotio regimen (iv-hepadn and 
coumadin) and 30 were treated by low-molecular-weight heparin, t~opidine 
and aspirin; 3 patients had a myocardial infarction; no other major compli- 
cations occurred; 41 patients (47%) were anpographically reevaluated at a 
mean of 7 ~ 4 months; 12 of them (29°/,,) showe'~ rastenesis. 
Conclusions: Elective stent treatment may b~ ~f benefit in unstable pa- 
tients with thrembus containing slenosis. The thrL. Lbegenic ombination of 
preexistir~ threntbu~, a.-.,'J .Petal, paradoxically, do~ ~ ;'~t preclude a good 
outcome. 
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.Prel!m!na~. Experience With the POSSIS Coronary 
Anglo~et Hneolytic i nromoectomy Catheter in the 
VEGAS I Pilot Study 
Stephen R, Ramea, Richard E. Kuntz, Richard A. Schatz, Joseph 
P. Carrozza, Jeffrey J. Pupma. Alyce S. Lenoue, Cynthia Senerchia, Robert 
C. $ioler, Kaion K.L. He, Donald S. Balm. Ochsner Hospital, New Orleans. 
LA; Beth Israel Hospital, Boston, MA 
The curre~ peroutaneous treatment of thrombotic obetructians in native 
coronary attefle~ (NC) or saphenous vein grafts (SVG) is limited by dis- 
tal embolizalion and incomplete evacuation or dissolution in many cases. 
The POSSIS AngioJet catheter removes intravasculer thrombus bodies by 
rbeolytio thmmbectomy: a Venturi effect created by precisely directed high 
pressure saline jets located at the tip of the 5 French over-the-wire catheter, 
The VEGAS I Pilot study ,,~ill evaluate the AngioJet in saphenous vein grafts 
and native coronary arteries. In 15 lesions treated in the first 15 patients, 8 
were in SVG and 7 in NC (including 3 patients with acute myocardial infarc- 
tion). Thrombotic appearing obstructions were successfully reduced in 14 of 
the 15 (93%) cases with AngioJet alone from 91 :E 18% diameter stenssis 
to 44 :t: 22% (visual estimates). In the one unsucces~l case, the undeity. 
ing stsnosis was concluded to be non-thmmbetic. In all cases, subsequent 
treatment included balloon angiopiasty in 2, directional atherectomy in 1, and 
Palrnaz-Sctlatz stenttng in 12, for final residual diameter stenesis of 5 ± 12%. 
Complications included transient heart block ~.~quiring temporary pacing in 
6, and tt'ansient "no inflow" in 2. 
Condus/on: 1) The AngioJet removes intravascuiar thmml~s in SVGs 
and native coronary arteries with high success and low complication rates. 2) 
Successful thrembus removal appear~ to prepare the vessel for subsequent 
safe and uncomplicated treatment by stenting, balloon angiopiasty, or direc- 
tional alhamcton~,. 3) The final results of this 60 patient pilot study should 
provide the background experience for the phase 2 randomized trial, VEGAS 
II. 
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1723-1 ~ The Relative Value of the Natrlumtio Peptides as 
Markers for Detecting Abnormal Ventricular 
Structure and Function 
Kazuh[re Yamamoto, John C, Bumett, Jr., Michihisa Jougasaki, 
Yoshihiko Sa-ito, Kazuwa Nakao, David R. Holmes, Jr., Margaret 
M, Redfield. Mayo Clinic, Rochester, MN 
Previous studies have suggested that brain and C- and N-terminal atrial 
natriuretic peptides (BNP. C-ANR N.ANP) may have diagnostic utility in the 
detection of LV hypertrophy (LVH) or LV dysfunction. The current study was 
designed to Jetennine the relative utility of measuring serum levels of BNR 
C.ANP or N-ANP to detect LVH or systolic or diastolic dysfunction. BNP 
(Shloncgi), C-ANP (Peninsula) and N-ANP (Phoenix) were determined by 
redioimmunsassay, ejection fraction (EF) and LV mass index were measured 
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